|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Protara Therapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Protara Therapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
9-15-2022 Insider Buy |
Opaleye Management Inc. >10% Owner |
$3.92
CAGR »
|
$93,808.00 23,900 shares |
8-11-2022 Insider Buy |
Jesse Shefferman CEO and President |
$3.84
CAGR »
|
$34,809.60 9,065 shares |
4-8-2022 Insider Buy |
Opaleye Management Inc. >10% Owner |
$4.78
CAGR »
|
$48,486.88 10,136 shares |
3-14-2022 Insider Buy |
Luke M. Beshar Director |
$4.25
CAGR »
|
$42,500.00 10,000 shares |
3-10-2022 Insider Buy |
Luke M. Beshar Director |
$4.46
CAGR »
|
$44,555.00 10,000 shares |
1-28-2022 Insider Buy |
Opaleye Management Inc. >10% Owner |
$4.96
CAGR »
|
$119,270.66 24,031 shares |
12-29-2021 Insider Buy |
Opaleye Management Inc. >10% Owner |
$6.60
CAGR »
|
$76,498.00 11,591 shares |
12-27-2021 Insider Buy |
Opaleye Management Inc. >10% Owner |
$6.53
CAGR »
|
$248,293.39 38,000 shares |
12-20-2021 Insider Buy |
Opaleye Management Inc. >10% Owner |
$6.49
CAGR »
|
$4,562.47 703 shares |
11-18-2021 Insider Buy |
Opaleye Management Inc. >10% Owner |
$6.98
CAGR »
|
$169,773.92 24,324 shares |
11-4-2021 Insider Buy |
Opaleye Management Inc. >10% Owner |
$6.50
CAGR »
|
$42,620.50 6,557 shares |
9-30-2020 Insider Buy |
Opaleye Management Inc. >10% Owner |
$16.00
CAGR »
|
$800,000.00 50,000 shares |
9-22-2020 Insider Buy |
Blaine Davis Chief Financial Officer |
$16.91
CAGR »
|
$25,037.79 1,481 shares |
Also See: Institutional Holders of TARA
Also See: SEC filings
Below we present the annualized performance delivered by Protara Therapeutics stock since 9-15-2022 (the date of the most recent
insider purchase). The performance of the investment from the time Protara Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about TARA being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
09/16/2022 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$3.66 |
|
End price/share: |
$2.92 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-20.08% |
|
Average Annual Total Return: |
-12.99% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$7,991.87 |
|
Years: |
1.61 |
|
Protara Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Protara Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding TARA
|
|